Article Text

PDF
Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
  1. M P Ávila1,
  2. M E Farah2,
  3. A Santos3,
  4. J P Duprat2,
  5. B W Woodward4,
  6. J Nau4
  1. 1
    Centro de Referência em Oftalmologia, Universidade Federal de Goiás, Goiânia, Brazil
  2. 2
    Departamento de Oftalmologia, Universidade Federal de São Paulo, São Paulo, Brazil
  3. 3
    Centro de Retina Médica y Quirúrgica, SC, Centro Medico Puerta de Hierro, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
  4. 4
    NeoVista, Fremont, California, USA
  1. Dr M P Ávila, Centro Brasileiro de Cirurgia de Olhos, CEP 74210-010 Goiânia—Goiás, Brazil; retina{at}cbco.com.br

Abstract

Background/aims: This study evaluated the short-term safety and feasibility of epiretinal strontium-90 brachytherapy delivered concomitantly with intravitreal bevacizumab for the treatment of subfoveal CNV due to AMD for 12 months. A 3-year follow-up is planned.

Methods: In this prospective, non-randomised, multicentre study, 34 treatment-naïve patients with predominantly classic, minimally classic and occult subfoveal CNV lesions received a single treatment with 24 Gy beta radiation (strontium-90) and two injections of the anti-VEGF antibody bevacizumab. Adverse events were observed. BCVA was measured using standard ETDRS vision charts.

Results: Twelve months after treatment, no radiation-associated adverse events were observed. In the intent-to-treat (ITT) population, 91% of patients lost <3 lines (15 ETDRS letters) of vision at 12 months, 68% improved or maintained their BCVA at 12 months, and 38% gained ⩾3 lines. The mean change in BCVA observed at month 12 was a gain of 8.9 letters.

Conclusion: The safety and efficacy of intraocular, epiretinal brachytherapy delivered concomitantly with anti-VEGF therapy for the treatment of subfoveal CNV secondary to AMD were promising in this small study population. Long-term safety will be assessed for 3 years. This regimen is being evaluated in a large, multicentre, phase III study.

Statistics from Altmetric.com

Footnotes

  • Competing interests: BWW and JN are employed by NeoVista, and have a proprietary interest in the investigational device.

  • Ethics approval: Ethics approval was provided by Centro Oftalmologico Ethics Committee, São Paulo, Brazil; Centro Brasileiro de Cirurgia de Oihos Ethics Committee, Goina, Brazil; and Universidad de Guadalajara Ethics Committee, Guadalajara, Jalisco, Mexico.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles